April 30th 2025
The company’s intent is to establish Merck Wilmington Biotech as the future United States home for producing Keytruda for US patients.
The evolution of therapeutic modalities drives the adoption of single-use technologies.
Gallus BioPharmaceuticals Uses ambr15 Micro Bioreactor to Develop Novel Antibodies and Biosimilars
April 30th 2014TAP Biosystems announced that Gallus BioPharmaceuticals is using its ambr15 micro bioreactor system to optimize process development and clone selection of novel antibody therapeutics and biosimilars.